Recro Pharma Inc. (NASDAQ:REPH)’s share price traded down 2.6% during mid-day trading on Monday . The stock traded as low as $7.71 and last traded at $7.74, with a volume of 119,379 shares changing hands. The stock had previously closed at $7.95.

Several equities analysts have issued reports on the stock. Zacks Investment Research downgraded shares of Recro Pharma from a “buy” rating to a “hold” rating in a report on Wednesday, May 18th. Brean Capital reissued a “buy” rating and issued a $28.00 price target on shares of Recro Pharma in a research note on Friday, May 13th. Finally, HC Wainwright reissued a “buy” rating on shares of Recro Pharma in a research note on Saturday, May 14th.

The firm’s market cap is $73.19 million. The firm has a 50-day moving average of $8.05 and a 200-day moving average of $7.27.

Recro Pharma (NASDAQ:REPH) last posted its earnings results on Thursday, May 12th. The specialty pharmaceutical company reported ($0.71) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.66) by $0.05. The company had revenue of $17.70 million for the quarter, compared to analysts’ expectations of $13 million. On average, analysts anticipate that Recro Pharma Inc. will post ($3.41) EPS for the current year.

In other Recro Pharma news, major shareholder Scp Vitalife Partners (Israel) sold 6,260 shares of the stock in a transaction that occurred on Friday, May 20th. The shares were sold at an average price of $6.46, for a total value of $40,439.60. Following the completion of the sale, the insider now owns 783,642 shares of the company’s stock, valued at $5,062,327.32. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Winston J. Churchill sold 58,331 shares of the stock in a transaction that occurred on Friday, May 20th. The shares were sold at an average price of $7.91, for a total transaction of $461,398.21. The disclosure for this sale can be found here.

Recro Pharma, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in developing non-opioid therapeutics for the treatment of pain, initially for acute pain following surgery. The Company’s lead product is an intranasal formulation of Dexmedetomidine (Dex). Its product candidates for pain indications include: Dex-IN, Dex-SL and Fadolmidine (Fado).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.